Antineurodegenerative and Antidiabetic Activity of Lichens

  • Marijana Kosanić
  • Branislav Ranković


Neurodegenerative diseases are phenomena that occur in the central nervous system through the hallmarks associating the loss of neuronal structure and function. These diseases affect many of our body’s activities, such as balance, movement, talking, breathing, and heart function. These disorders are very common and their frequency increases with age, in mid-to-late adult life. Except neurodegeneration, a very common disease is diabetes mellitus. Diabetes mellitus is a chronic disease caused by inherited and/or acquired deficiency in the production of insulin by the pancreas or by the ineffectiveness of the insulin produced. Such a deficiency results in increased concentrations of glucose in the blood, which in turn damage many of the body’s systems. Since the past few decades, diabetes has become a global health problem. Apart from conventional therapy, several studies have shown that some natural products have beneficial effects in neurological and diabetic patients. Various natural products emerged as interesting molecules with antineurodegenerative and antidiabetic potential. However, little is known in relation to lichens as potential therapeutics in these disorders. Therefore, this chapter focuses on the antineurodegenerative and antidiabetic potential of lichens that have received considerable attention in the recent past.


  1. Abusufyan S, Ibrahim M, Mohib K (2018) Comparative in vitro antidiabetic and antioxidant activity of various extracts of Ficus species. Pharm J 10:349–354Google Scholar
  2. Ataie A, Shadifar M, Ataee R (2016) Polyphenolic antioxidants and neuronal regeneration. Basic Clin Neurosci 7:81–90PubMedPubMedCentralGoogle Scholar
  3. Barquilla García A (2017) Brief update on diabetes for general practitioners. Rev Esp Sanid Penit 19:57–65PubMedGoogle Scholar
  4. Baynes HW (2015) Classification, pathophysiology, diagnosis and management of diabetes mellitus. J Diabetes Metab 6:541Google Scholar
  5. Behera BC, Adawadkar B, Makhija U (2004) Capacity of some Graphidaceous lichens to scavenge superoxide and inhibition of tyrosinase and xanthine oxidase activities. Curr Sci 87:83–87Google Scholar
  6. Berger J, Wagner JA (2002) Physiological and therapeutic roles of peroxisome proliferatoractivated receptors. Diabetes Technol Ther 4:163–174CrossRefGoogle Scholar
  7. Chonpathompikunlert P, Boonruamkaew P, Sukketsiri W et al (2018) The antioxidant and neurochemical activity of Apium graveolens L. and its ameliorative effect on MPTP-induced Parkinson-like symptoms in mice. BMC Complement Altern Med 18:103CrossRefGoogle Scholar
  8. Choudhary MI, Ali M, Wahab AT et al (2011) New antiglycation and enzyme inhibitors from Parmotrema cooperi. Sci China Chem 54:1926–1931CrossRefGoogle Scholar
  9. Crous-Bou M, Minguillón C, Gramunt N et al (2017) Alzheimer’s disease prevention: from risk factors to early intervention. Alzheimers Res Ther 9:71CrossRefGoogle Scholar
  10. Cui Y, Yim JH, Lee DS et al (2012) New diterpene furanoids from the Antarctic lichen Huea sp. Bioorg Med Chem Lett 22:7393–7396CrossRefGoogle Scholar
  11. de Paz GA, Raggio J, Gómez-Serranillos MP et al (2010) HPLC isolation of antioxidant constituents from Xanthoparmelia spp. J Pharm Biomed Anal 53:165–171CrossRefGoogle Scholar
  12. Dsouza D, Lakshmidevi N (2015) Models to study in vitro antidiabetic activity of plants: a review. Int J Pharm Biol Sci 6:732–741Google Scholar
  13. Ellman GL, Courtney DK, Andreas V et al (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–95CrossRefGoogle Scholar
  14. Emsen B, Aslan A, Togar B et al (2016) In vitro antitumor activities of the lichen compounds olivetoric, physodic and psoromic acid in rat neuron and glioblastoma cells. Pharm Biol 54:1748–1762CrossRefGoogle Scholar
  15. Evans RM, Barish GD, Wang YX (2004) PPARs and the complex journey to obesity. Nat Med 10:355–361CrossRefGoogle Scholar
  16. Fernandez-Moriano C, Divakar PK, Crespo A et al (2015) Neuroprotective activity and cytotoxic potential of two Parmeliaceae lichens: identification of active compounds. Phytomedicine 22:847–855CrossRefGoogle Scholar
  17. Fernández-Moriano C, Divakar PK, Crespo A et al (2017) In vitro neuroprotective potential of lichen metabolite fumarprotocetraric acid via intracellular redox modulation. Toxicol Appl Pharmacol 316:83–94CrossRefGoogle Scholar
  18. Griess P (1879) Bemerkungen zu der abhandlung der H.H. Weselsky und Benedikt “Ueber einige azoverbindungen”. Chem Ber 12:426–428CrossRefGoogle Scholar
  19. Gupta RC, Chang D, Nammi S et al (2017) Interactions between antidiabetic drugs and herbs: an overview of mechanisms of action and clinical implications. Diabetol Metab Syndr 9:59CrossRefGoogle Scholar
  20. Haj FG, Markova B, Klaman LD et al (2003) Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B. J Biol Chem 278:739–744CrossRefGoogle Scholar
  21. Hengameh P, Shivanna R, Rajkumar HG (2016) In-vitro inhibitory activity of some lichen extracts against FC;-amylase enzyme. Eur J Biomed Pharm Sci 3:315–318Google Scholar
  22. Hippius H, Neundörfer G (2003) The discovery of Alzheimer’s disease. Dialogues Clin Neurosci 5:101–108PubMedPubMedCentralGoogle Scholar
  23. Honda NK, Gonçalves K, Brandão LZG et al (2016) Screening of lichen extracts using tyrosinase inhibition and toxicity against Artemia salina. Orbital Electron J Chem 8:181–188Google Scholar
  24. Ikeda T, Yamada M (2010) Risk factors for Alzheimer’s disease. Brain Nerve 62:679–690PubMedGoogle Scholar
  25. Jack CR Jr, Albert MS, Knopman DS et al (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 7:257–262CrossRefGoogle Scholar
  26. Karunaratne V, Thadhani VM, Khan SN et al (2014) Potent FC;-glucosidase inhibitors from the lichen Cladonia species from Sri Lanka. J Natl Sci Found Sri Lanka 42:95–98CrossRefGoogle Scholar
  27. Khan MF, Rawat AK, Khatoon S et al (2018) In vitro and in vivo antidiabetic effect of extracts of Melia azedarach, Zanthoxylum alatum, and Tanacetum nubigenum. Integr Med Res 7:176–183CrossRefGoogle Scholar
  28. Kim GH, Kim JE, Rhie SJ et al (2015) The role of oxidative stress in neurodegenerative diseases. Exp Neurobiol 24:325–340CrossRefGoogle Scholar
  29. Kim M, Ho A, Lee JH (2017) Autophagy and human neurodegenerative diseases—a fly’s perspective. Int J Mol Sci 18:1596CrossRefGoogle Scholar
  30. Kremens D, Hauser RA, Dorsey ER (2014) An update on Parkinson’s disease: improving patient outcomes. Am J Med 127:S3CrossRefGoogle Scholar
  31. Liu Z, Zhou T, Ziegler AC et al (2017) Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications. Oxid Med Cell Longev 2017:2525967PubMedPubMedCentralGoogle Scholar
  32. Luo H, Li C, Kim JC et al (2013) Biruloquinone, an acetylcholinesterase inhibitor produced by lichen-forming fungus Cladonia macilenta. J Microbiol Biotechnol 23:161–166CrossRefGoogle Scholar
  33. Parimelazhagan T (2016) Anti-diabetic activity. In: Parimelazhagan T (ed) Pharmacological assays of plant-based natural products. Springer, Cham, pp 139–143CrossRefGoogle Scholar
  34. Paudel B, Bhattarai HD, Koh HY et al (2011) Ramalin, a novel nontoxic antioxidant compound from the Antarctic lichen Ramalina terebrata. Phytomedicine 184:1285–1290CrossRefGoogle Scholar
  35. Paulson HL (2009) The spinocerebellar ataxias. J Neuroophthalmol 29:227–237CrossRefGoogle Scholar
  36. Pejin B, Tommonaro G, Iodice C et al (2013) A new depsidone of Lobaria pulmonaria with acetylcholinesterase inhibition activity. J Enzyme Inhib Med Chem 28:876–878CrossRefGoogle Scholar
  37. Pratt AJ, Getzoff ED, Perry JJ (2012) Amyotrophic lateral sclerosis: update and new developments. Degener Neurol Neuromuscul Dis 2:1–14PubMedCentralGoogle Scholar
  38. Reddy RG, Veeraval L, Maitra S et al (2016) Lichen-derived compounds show potential for central nervous system therapeutics. Phytomedicine 23:1527–1534CrossRefGoogle Scholar
  39. Roos RA (2010) Huntington’s disease: a clinical review. Orphanet J Rare Dis 5:40CrossRefGoogle Scholar
  40. Saito K, Lee S, Shiuchi T et al (2011) An enzymatic photometric assay for 2-deoxyglucose uptake in insulin-responsive tissues and 3T3-L1 adipocytes. Anal Biochem 412:9–17CrossRefGoogle Scholar
  41. Seo C, Choi YH, Ahn JS et al (2009a) PTP1B inhibitory effects of tridepside and related metabolites isolated from the Antarctic lichen Umbilicaria antarctica. J Enzyme Inhib Med Chem 24:1133–1137CrossRefGoogle Scholar
  42. Seo C, Sohn JH, Ahn JS et al (2009b) Protein tyrosine phosphatase 1B inhibitory effects of depsidone and pseudodepsidone metabolites from the Antarctic lichen Stereocaulon alpinum. Bioorg Med Chem Lett 19:2801–2803CrossRefGoogle Scholar
  43. Seo C, Yim JH, Lee HK et al (2011) PTP1B inhibitory secondary metabolites from the Antarctic lichen Lecidella carpathica. Mycology 2:18–23CrossRefGoogle Scholar
  44. Shivanna R, Hengameh P, Rajkumar HG (2015) Screening of lichen extracts for in-vitro antidiabetic activity using alpha amylase inhibitory assay. Int J Biol Pharm Res 6:364–367Google Scholar
  45. Thadhani VM (2013) Semisynthesis and bioactivities of lichen metabolites. Scholars’ Press, SaarbrückenGoogle Scholar
  46. Thadhani VM, Karunaratne V (2017) Potential of lichen compounds as antidiabetic agents with antioxidative properties: a review. Oxid Med Cell Longev 2017:2079697CrossRefGoogle Scholar
  47. Thadhani VM, Naaz Q, Choudhag MI et al (2014) Enzyme inhibitory and immunomodulatory activities of the depsidone lobaric acid extracted from the lichen Heterodermia sp. J Natl Sci Found Sri Lanka 42:193–196CrossRefGoogle Scholar
  48. Valadbeigi T (2016) Chemical composition and enzymes inhibitory, brine shrimp larvae toxicity, antimicrobial and antioxidant activities of Caloplaca biatorina. Zahedan J Res Med Sci 18:e4267Google Scholar
  49. Valadbeigi T, Shaddel M (2016) Amylase inhibitory activity of some macro lichens in Mazandaran province, Iran. Physiol Pharmacol 20:215–219Google Scholar
  50. Valley MP, Karassina N, Aoyama N et al (2016) A bioluminescent assay for measuring glucose uptake. Anal Biochem 505:43–50CrossRefGoogle Scholar
  51. Verma N, Behera BC, Sonone A et al (2008) Lipid peroxidation and tyrosinase inhibition by lichen symbionts grown in vitro. Afr J Biochem Res 2:225–231Google Scholar
  52. Verma N, Behera BC, Om Sharma B (2012) Glucosidase inhibitory and radical scavenging properties of lichen metabolites salazinic acid, sekikaic acid and usnic acid. Hacettepe J Biol Chem 40:7–21Google Scholar
  53. Villhauer EB, Brinkman JA, Naderi GB et al (2003) 1-[(3-hydroxy-1 adamantyl) amino acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 46:2774–2789CrossRefGoogle Scholar
  54. Vinayaka KS, Karthik S, Nandini KC et al (2013) Amylase inhibitory activity of some macrolichens of western ghats, Karnataka, India. Indian J Novel Drug Deliv 5:225–228Google Scholar
  55. Yamamoto N, Ueda-Wakagi M, Sato T et al (2015) Measurement of glucose uptake in cultured cells. Curr Protoc Pharmacol 71:12.14.1–12.14.26CrossRefGoogle Scholar
  56. Zlatanović I, Stanković M, Stankov-Jovanović V et al (2017) Biological activities of Umbilicaria crustulosa (Ach.) Frey acetone extract. J Serb Chem Soc 82:141–150CrossRefGoogle Scholar
  57. Zrnzević I, Stanković M, Stankov Jovanovic V et al (2017) Ramalina capitata (Ach.) Nyl. acetone extract: HPLC analysis, genotoxicity, cholinesterase, antioxidant and antibacterial activity. EXCLI J 16:679–687PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Marijana Kosanić
    • 1
  • Branislav Ranković
    • 1
  1. 1.Department of Biology, Faculty of ScienceUniversity of KragujevacKragujevacSerbia

Personalised recommendations